An integrative view on the cell-type-specific mechanisms of ketamine's antidepressant actions

Trends Neurosci. 2024 Jan 13:S0166-2236(23)00291-6. doi: 10.1016/j.tins.2023.12.004. Online ahead of print.ABSTRACTOver the past six decades, the use of ketamine has evolved from an anesthetic and recreational drug to the first non-monoaminergic antidepressant approved for treatment-resistant major depressive disorder (MDD). Subanesthetic doses of ketamine and its enantiomer (S)-ketamine (esketamine) directly bind to several neurotransmitter receptors [including N-methyl-d-aspartic acid receptor (NMDAR), κ and μ opioid receptor (KOR and MOR)] widely distributed in the brain and across different cell types, implicating several potential molecular mechanisms underlying the action of ketamine as an antidepressant. This review examines preclinical studies investigating cell-type-specific mechanisms underlying the effects of ketamine on behavior and synapses. Cell-type-specific approaches are crucial for disentangling the critical mechanisms involved in the therapeutic effect of ketamine.PMID:38220554 | DOI:10.1016/j.tins.2023.12.004
Source: Trends in Neurosciences - Category: Neuroscience Authors: Source Type: research